Other Species / Isoforms
  H3F3A (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
T3-p
_____ARtkQTARks
1 0
H3F3A (human) _____ARtkQTARks T3-p
H3F3A (mouse) _____ARTKQTARkS T3
K4-m1
____ARtkQTARksT
1 10
H3F3A (human) ____ARtkQTARksT K4-m1
H3F3A (mouse) ____ARTKQTARkST K4
K9-ac
RtkQTARksTGGkAP
1 59
H3F3A (human)
K9-ac
H3F3A (human) RtkQTARksTGGkAP K9-ac
H3F3A (mouse) RTKQTARkSTGGkAP K9-ac
K9-m1
RtkQTARksTGGkAP
1 15
H3F3A (human) RtkQTARksTGGkAP K9-m1
H3F3A (mouse) RTKQTARKSTGGkAP K9
K9-m2
RtkQTARksTGGkAP
1 0
H3F3A (human) RtkQTARksTGGkAP K9-m2
H3F3A (mouse) RTKQTARKSTGGkAP K9
K9-m3
RtkQTARksTGGkAP
1 0
H3F3A (human) RtkQTARksTGGkAP K9-m3
H3F3A (mouse) RTKQTARKSTGGkAP K9
S10-p
tkQTARksTGGkAPR
Upstream
Downstream
12 3
H3F3A (human)
S10-p
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • AurB (human)
  • Fyn (human)
  • PKACA (human)
Putative in vivo kinases:
  • AurB (human)
  • Fyn (human)
Regulatory protein:
  • Borealin (human)
Treatment
  • adriamycin
  • bicalutamide
  • fluid_shear_stress
  • nocodazole
  • PD98059
  • SB203580
  • siRNA
  • testosterone
  • thymidine
  • trichostatin_A
  • UV
  • wortmannin
H3F3A (human) tkQTARksTGGkAPR S10-p
H3F3A (mouse) TKQTARkSTGGkAPR S10
K14-ac
ARksTGGkAPRkQLA
1 61
H3F3A (human) ARksTGGkAPRkQLA K14-ac
H3F3A (mouse) ARkSTGGkAPRkQLA K14-ac
K18-ac
TGGkAPRkQLATkAA
0 57
H3F3A (human) TGGkAPRkQLATkAA K18-ac
H3F3A (mouse) TGGkAPRkQLATkAA K18-ac
K23-ac
PRkQLATkAARksAP
0 65
H3F3A (human) PRkQLATkAARksAP K23-ac
H3F3A (mouse) PRkQLATkAARKsAP K23-ac
K23-ub
PRkQLATkAARksAP
0 6
H3F3A (human) PRkQLATkAARksAP K23-ub
H3F3A (mouse) PRkQLATKAARKsAP K23
K27-ac
LATkAARksAPsTGG
0 23
H3F3A (human) LATkAARksAPsTGG K27-ac
H3F3A (mouse) LATkAARKsAPSTGG K27
K27-ub
LATkAARksAPsTGG
0 44
H3F3A (human) LATkAARksAPsTGG K27-ub
H3F3A (mouse) LATkAARKsAPSTGG K27
K27-m1
LATkAARksAPsTGG
1 41
H3F3A (human) LATkAARksAPsTGG K27-m1
H3F3A (mouse) LATkAARKsAPSTGG K27
K27-m2
LATkAARksAPsTGG
1 6
H3F3A (human) LATkAARksAPsTGG K27-m2
H3F3A (mouse) LATkAARKsAPSTGG K27
K27-m3
LATkAARksAPsTGG
1 5
H3F3A (human) LATkAARksAPsTGG K27-m3
H3F3A (mouse) LATkAARKsAPSTGG K27
S28-p
ATkAARksAPsTGGV
Upstream
4 11
Kinase, in vitro:
  • AurB (human)
  • PKACA (human)
Putative in vivo kinases:
  • AurB (human)
Treatment
  • MG132
  • MG132_withdrawal
  • nocodazole
H3F3A (human) ATkAARksAPsTGGV S28-p
H3F3A (mouse) ATkAARKsAPSTGGV S28-p
S31-p
AARksAPsTGGVkkP
Upstream
4 4
Kinase, in vitro:
  • Chk1 (human)
Putative in vivo kinases:
  • Chk1 (human)
Treatment
  • DTBR
  • nocodazole
  • phleomycin
  • SB218078
H3F3A (human) AARksAPsTGGVkkP S31-p
H3F3A (mouse) AARKsAPSTGGVKKP S31
K36-ac
APsTGGVkkPHryRP
0 23
H3F3A (human) APsTGGVkkPHryRP K36-ac
H3F3A (mouse) APSTGGVKKPHRyRP K36
K36-ub
APsTGGVkkPHryRP
0 28
H3F3A (human) APsTGGVkkPHryRP K36-ub
H3F3A (mouse) APSTGGVKKPHRyRP K36
K36-m1
APsTGGVkkPHryRP
1 42
H3F3A (human) APsTGGVkkPHryRP K36-m1
H3F3A (mouse) APSTGGVKKPHRyRP K36
K36-m2
APsTGGVkkPHryRP
1 5
H3F3A (human) APsTGGVkkPHryRP K36-m2
H3F3A (mouse) APSTGGVKKPHRyRP K36
K36-m3
APsTGGVkkPHryRP
1 3
H3F3A (human) APsTGGVkkPHryRP K36-m3
H3F3A (mouse) APSTGGVKKPHRyRP K36
K37-ac
PsTGGVkkPHryRPG
0 2
H3F3A (human) PsTGGVkkPHryRPG K37-ac
H3F3A (mouse) PSTGGVKKPHRyRPG K37
K37-ub
PsTGGVkkPHryRPG
0 2
H3F3A (human) PsTGGVkkPHryRPG K37-ub
H3F3A (mouse) PSTGGVKKPHRyRPG K37
K37-m1
PsTGGVkkPHryRPG
0 9
H3F3A (human) PsTGGVkkPHryRPG K37-m1
H3F3A (mouse) PSTGGVKKPHRyRPG K37
K37-m2
PsTGGVkkPHryRPG
0 2
H3F3A (human) PsTGGVkkPHryRPG K37-m2
H3F3A (mouse) PSTGGVKKPHRyRPG K37
K37-m3
PsTGGVkkPHryRPG
1 1
H3F3A (human) PsTGGVkkPHryRPG K37-m3
H3F3A (mouse) PSTGGVKKPHRyRPG K37
R40-m1
GGVkkPHryRPGtVA
0 3
H3F3A (human) GGVkkPHryRPGtVA R40-m1
H3F3A (mouse) GGVKKPHRyRPGtVA R40
Y41-p
GVkkPHryRPGtVAL
0 7
H3F3A (human) GVkkPHryRPGtVAL Y41-p
H3F3A (mouse) GVKKPHRyRPGtVAL Y41-p
T45-p
PHryRPGtVALREIR
Upstream
1 6
Kinase, in vitro:
  • DYRK1A (rat)
  • DYRK1B (human)
  • DYRK2 (human)
  • DYRK3 (human)
H3F3A (human) PHryRPGtVALREIR T45-p
H3F3A (mouse) PHRyRPGtVALREIR T45-p
Y54
ALREIRRYQkstELL
0 1
H3F3A (human) ALREIRRYQkstELL Y54
H3F3A (mouse) ALREIRRyQkstELL Y54-p
K56-ub
REIRRYQkstELLIR
Upstream
0 14
Treatment
  • MG132
  • vorinostat
H3F3A (human) REIRRYQkstELLIR K56-ub
H3F3A (mouse) REIRRyQkstELLIR K56-ub
K56-ac
REIRRYQkstELLIR
0 3
H3F3A (human) REIRRYQkstELLIR K56-ac
H3F3A (mouse) REIRRyQkstELLIR K56-ac
S57-p
EIRRYQkstELLIRK
0 22
H3F3A (human) EIRRYQkstELLIRK S57-p
H3F3A (mouse) EIRRyQkstELLIRK S57-p
T58-p
IRRYQkstELLIRKL
0 7
H3F3A (human) IRRYQkstELLIRKL T58-p
H3F3A (mouse) IRRyQkstELLIRKL T58-p
K79-ac
REIAQDFktDLRFQs
0 37
H3F3A (human) REIAQDFktDLRFQs K79-ac
H3F3A (mouse) REIAQDFktDLRFQS K79-ac
K79-m2
REIAQDFktDLRFQs
Downstream
0 5
Effects on Modified Protein
  • molecular association, regulation
H3F3A (human) REIAQDFktDLRFQs K79-m2
H3F3A (mouse) REIAQDFKtDLRFQS K79
K79-ub
REIAQDFktDLRFQs
Upstream
0 10
Treatment
  • MG132
H3F3A (human) REIAQDFktDLRFQs K79-ub
H3F3A (mouse) REIAQDFktDLRFQS K79-ub
T80-p
EIAQDFktDLRFQsA
0 31
H3F3A (human) EIAQDFktDLRFQsA T80-p
H3F3A (mouse) EIAQDFktDLRFQSA T80-p
S86-p
ktDLRFQsAAIGALQ
0 1
H3F3A (human) ktDLRFQsAAIGALQ S86-p
H3F3A (mouse) ktDLRFQSAAIGALQ S86
T107-p
LVGLFEDtNLCAIHA
0 2
H3F3A (human) LVGLFEDtNLCAIHA T107-p
H3F3A (mouse) LVGLFEDTNLCAIHA T107
K115-ac
NLCAIHAkRVTIMPk
0 9
H3F3A (human) NLCAIHAkRVTIMPk K115-ac
H3F3A (mouse) NLCAIHAKRVTIMPk K115
K115-ub
NLCAIHAkRVTIMPk
0 3
H3F3A (human) NLCAIHAkRVTIMPk K115-ub
H3F3A (mouse) NLCAIHAKRVTIMPk K115
K122-ac
kRVTIMPkDIQLARR
0 3
H3F3A (human) kRVTIMPkDIQLARR K122-ac
H3F3A (mouse) KRVTIMPkDIQLARR K122-ac